1-19 of 19
Mitchell Dowsett
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P4-02-05: Exploiting novel models of endocrine-resistant breast cancer to identify new therapeutic targets

Arany Soosainathan, Joanna Nikitorowicz-Buniak, Sunil Pancholi, Marjan Iravani, John Alexander, Syed Haider, Stephen R Johnston, Mitchell Dowsett, Lesley A Martin, Clare M Isacke
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-02-05.
https://doi.org/10.1158/1538-7445.SABCS21-P4-02-05
Published: 15 February 2022
View article titled, Abstract P4-02-05: Exploiting novel models of endocrine-resistant breast cancer to identify new therapeutic targets
Journal Articles

Abstract P5-06-04: Prognostic value of EndoPredict and Oncotype Recurrence Score according to patient's age

Ivana Sestak, Ralf Kronenwett, Richard Buus, Jack Cuzick, Mitchell Dowsett
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P5-06-04.
https://doi.org/10.1158/1538-7445.SABCS19-P5-06-04
Published: 15 February 2020
View article titled, Abstract P5-06-04: Prognostic value of EndoPredict and Oncotype Recurrence Score according to patient's age
Journal Articles

Abstract P5-06-05: Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer

Ivana Sestak, Sean Ferree, Itay Shemesh, Wesley Buckingham, Jack Cuzick, Mitchell Dowsett
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P5-06-05.
https://doi.org/10.1158/1538-7445.SABCS19-P5-06-05
Published: 15 February 2020
View article titled, Abstract P5-06-05: Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer
Journal Articles

Abstract GS2-04: Improvements in long-term outcome for women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database

Hongchao Pan, Jeremy Braybrooke, Richard Gray, Richard Peto, Rosie Bradley, Robert Hills, Jonas Bergh, Sandra M Swain, Mitchell Dowsett, Daniel F Hayes, Richard D Gelber, for the EBCTCG
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): GS2-04.
https://doi.org/10.1158/1538-7445.SABCS19-GS2-04
Published: 15 February 2020
View article titled, Abstract GS2-04: Improvements in long-term outcome for women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database
Journal Articles

Abstract GS4-04: Ten year results of the international breast cancer intervention study II

Jack Cuzick, Ivana Sestak, John Forbes, Mitchell Dowsett, Simon Cawthorn, Robert Mansell, Sibylle Loibl, Bernardo Bonanni, Anthony Howell, IBIS-II investigators
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): GS4-04.
https://doi.org/10.1158/1538-7445.SABCS19-GS4-04
Published: 15 February 2020
View article titled, Abstract GS4-04: Ten year results of the international breast cancer intervention study II
Journal Articles

Abstract GS4-03: Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study

Ivana Sestak, Michael Crager, Jack Cuzick, Mitchell Dowsett, Steven Shak, Gong Tang, Robert Gray, Joseph Sparano
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): GS4-03.
https://doi.org/10.1158/1538-7445.SABCS19-GS4-03
Published: 15 February 2020
View article titled, Abstract GS4-03: Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study
Journal Articles

Abstract BL-2: What relevance have hormones for breast cancer in the genomic era?

Mitchell Dowsett
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): BL-2.
https://doi.org/10.1158/1538-7445.SABCS14-BL-2
Published: 01 May 2015
View article titled, Abstract BL-2: What relevance have hormones for breast cancer in the genomic era?
Journal Articles

Abstract ES3-2: Biomarkers for clinical management and research

Mitchell Dowsett
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): ES3-2.
https://doi.org/10.1158/1538-7445.SABCS14-ES3-2
Published: 01 May 2015
View article titled, Abstract ES3-2: Biomarkers for clinical management and research
Journal Articles

Premenopausal Mammographic Density in Relation to Cyclic Variations in Endogenous Sex Hormone Levels, Prolactin, and Insulin-like Growth Factors

Kate Walker, Olivia Fletcher, Nichola Johnson, Ben Coupland, Valerie A. McCormack, Elizabeth Folkerd, Lorna Gibson, Stephen G. Hillier, Jeff M. Holly, Sue Moss, Mitchell Dowsett, Julian Peto, Isabel dos Santos Silva
Journal: Cancer Research
Cancer Res (2009) 69 (16): 6490–6499.
https://doi.org/10.1158/0008-5472.CAN-09-0280
Published: 12 August 2009
View article titled, Premenopausal Mammographic Density in Relation to Cyclic Variations in Endogenous Sex Hormone Levels, Prolactin, and Insulin-like Growth Factors
Open the PDF for Premenopausal Mammographic Density in Relation to Cyclic Variations in Endogenous Sex Hormone Levels, Prolactin, and Insulin-like Growth Factors in another window
Includes: Supplementary data
Journal Articles

Comparison of the Short-Term Biological Effects of 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17β-diol (Faslodex) versus Tamoxifen in Postmenopausal Women with Primary Breast Cancer

John F. Robertson, Robert I. Nicholson, Nigel J. Bundred, Elizabeth Anderson, Zenon Rayter, Mitchell Dowsett, John N. Fox, Julia M. W. Gee, Alan Webster, Alan E. Wakeling, Charles Morris, Michael Dixon
Journal: Cancer Research
Cancer Res (2001) 61 (18): 6739–6746.
Published: 01 September 2001
View article titled, Comparison of the Short-Term Biological Effects of 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17β-diol (Faslodex) <em>versus</em> Tamoxifen in Postmenopausal Women with Primary Breast Cancer
Open the PDF for Comparison of the Short-Term Biological Effects of 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17β-diol (Faslodex) <em>versus</em> Tamoxifen in Postmenopausal Women with Primary Breast Cancer in another window
Journal Articles

Comparison of Estrogen Receptor DNA Binding in Untreated and Acquired Antiestrogen-resistant Human Breast Tumors

Stephen R. D. Johnston, B. Lu, Mitchell Dowsett, X. Liang, Manfred Kaufmann, Gary K. Scott, C. Kent Osborne, Christopher C. Benz
Journal: Cancer Research
Cancer Res (1997) 57 (17): 3723–3727.
Published: 01 September 1997
View article titled, Comparison of Estrogen Receptor DNA Binding in Untreated and Acquired Antiestrogen-resistant Human Breast Tumors
Open the PDF for Comparison of Estrogen Receptor DNA Binding in Untreated and Acquired Antiestrogen-resistant Human Breast Tumors in another window
Journal Articles

Idoxifene: Report of a Phase I Study in Patients with Metastatic Breast Cancer

R. Charles Coombes, Ben P. Haynes, Mitchell Dowsett, Mary Quigley, Jacqueline English, Ian R. Judson, Lesley J. Griggs, Gerry A. Potter, Ray McCague, Michael Jarman
Journal: Cancer Research
Cancer Res (1995) 55 (5): 1070–1074.
Published: 01 March 1995
View article titled, Idoxifene: Report of a Phase I Study in Patients with Metastatic Breast Cancer
Open the PDF for Idoxifene: Report of a Phase I Study in Patients with Metastatic Breast Cancer in another window
Journal Articles

Exon 5 Deletion Variant Estrogen Receptor Messenger RNA Expression in Relation to Tamoxifen Resistance and Progesterone Receptor/pS2 Status in Human Breast Cancer

Angela A. I. Daffada, Stephen R. D. Johnston, Ian E. Smith, Simone Detre, Nicholas King, Mitchell Dowsett
Journal: Cancer Research
Cancer Res (1995) 55 (2): 288–293.
Published: 01 January 1995
View article titled, Exon 5 Deletion Variant Estrogen Receptor Messenger RNA Expression in Relation to Tamoxifen Resistance and Progesterone Receptor/pS2 Status in Human Breast Cancer
Open the PDF for Exon 5 Deletion Variant Estrogen Receptor Messenger RNA Expression in Relation to Tamoxifen Resistance and Progesterone Receptor/pS2 Status in Human Breast Cancer in another window
Journal Articles

Clinical and Endocrine Effects of the Oral Aromatase Inhibitor Vorozole in Postmenopausal Patients with Advanced Breast Cancer

Stephen R. D. Johnston, Ian E. Smith, Deborah Doody, Stephen Jacobs, Hazel Robertshaw, Mitchell Dowsett
Journal: Cancer Research
Cancer Res (1994) 54 (22): 5875–5881.
Published: 01 November 1994
View article titled, Clinical and Endocrine Effects of the Oral Aromatase Inhibitor Vorozole in Postmenopausal Patients with Advanced Breast Cancer
Open the PDF for Clinical and Endocrine Effects of the Oral Aromatase Inhibitor Vorozole in Postmenopausal Patients with Advanced Breast Cancer in another window
Journal Articles

Investigation of a New Pure Antiestrogen (ICI 182780) in Women with Primary Breast Cancer

David J. DeFriend, Anthony Howell, Robert I. Nicholson, Elizabeth Anderson, Mitchell Dowsett, Robert E. Mansel, Roger W. Blamey, Nigel J. Bundred, John F. Robertson, Christobel Saunders, Michael Baum, Peter Walton, Frances Sutcliffe, Alan E. Wakeling
Journal: Cancer Research
Cancer Res (1994) 54 (2): 408–414.
Published: 01 January 1994
View article titled, Investigation of a New Pure Antiestrogen (ICI 182780) in Women with Primary Breast Cancer
Open the PDF for Investigation of a New Pure Antiestrogen (ICI 182780) in Women with Primary Breast Cancer in another window
Journal Articles

Induction of Transforming Growth Factor β1 in Human Breast Cancer in Vivo following Tamoxifen Treatment

Anju Butta, Kenneth MacLennan, Kathleen C. Flanders, Nigel P. M. Sacks, Ian Smith, Alan McKinna, Mitchell Dowsett, Lalage M. Wakefield, Michael B. Sporn, Michael Baum, Anthony A. Colletta
Journal: Cancer Research
Cancer Res (1992) 52 (15): 4261–4264.
Published: 01 August 1992
View article titled, Induction of Transforming Growth Factor β<sub>1</sub> in Human Breast Cancer <em>in Vivo</em> following Tamoxifen Treatment
Open the PDF for Induction of Transforming Growth Factor β<sub>1</sub> in Human Breast Cancer <em>in Vivo</em> following Tamoxifen Treatment in another window
Journal Articles

Steroid and Growth Factor Modulation of Aromatase Activity in MCF7 and T47D Breast Carcinoma Cell Lines

Carolyn M. Ryde, Joanne E. Nicholls, Mitchell Dowsett
Journal: Cancer Research
Cancer Res (1992) 52 (6): 1411–1415.
Published: 01 March 1992
View article titled, Steroid and Growth Factor Modulation of Aromatase Activity in MCF7 and T47D Breast Carcinoma Cell Lines
Open the PDF for Steroid and Growth Factor Modulation of Aromatase Activity in MCF7 and T47D Breast Carcinoma Cell Lines in another window
Journal Articles

Preliminary Study of the Treatment of Advanced Breast Cancer in Postmenopausal Women with the Aromatase Inhibitor CGS 16949A

Robert C. Stein, Mitchell Dowsett, Joanna Davenport, Anthea Hedley, Hubert T. Ford, Jean-Claude Gazet, R. Charles Coombes
Journal: Cancer Research
Cancer Res (1990) 50 (5): 1381–1384.
Published: 01 March 1990
View article titled, Preliminary Study of the Treatment of Advanced Breast Cancer in Postmenopausal Women with the Aromatase Inhibitor CGS 16949A
Open the PDF for Preliminary Study of the Treatment of Advanced Breast Cancer in Postmenopausal Women with the Aromatase Inhibitor CGS 16949A in another window
Journal Articles

Treatment of Advanced Postmenopausal Breast Cancer with an Aromatase Inhibitor, 4-Hydroxyandrostenedione: Phase II Report

Paul E. Goss, Trevor J. Powles, Mitchell Dowsett, Gillian Hutchison, Angela M. H. Brodie, Jean-Claud Gazet, R. Charles Coombes
Journal: Cancer Research
Cancer Res (1986) 46 (9): 4823–4826.
Published: 01 September 1986
View article titled, Treatment of Advanced Postmenopausal Breast Cancer with an Aromatase Inhibitor, 4-Hydroxyandrostenedione: Phase II Report
Open the PDF for Treatment of Advanced Postmenopausal Breast Cancer with an Aromatase Inhibitor, 4-Hydroxyandrostenedione: Phase II Report in another window